Skip to main content

Hematologic Diseases

6
Pipeline Programs
17
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
2
0
0
2
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

17 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
2 programs
1
Detection of microbial DNA in blood by SeptiFast TestPhase 4
NewSpringForMe digital solutionN/A
Genentech
GenentechCA - Oceanside
1 program
1
Detection of microbial DNA in blood by SeptiFast TestPhase 41 trial
Active Trials
NCT01114165Completed150Est. Sep 2012
MSD
MSDIreland - Ballydine
1 program
1
OndansetronPhase 21 trial
Active Trials
NCT00954941Completed100Est. May 2015
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
OndansetronPhase 2
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
GSK4172239DPhase 1
Pulmotect
PulmotectTX - Houston
1 program
1
PUL-042Phase 11 trial
Active Trials
NCT03097796Withdrawn0Est. May 2026
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
2 programs
NewSpringForMe digital solutionN/A
NewSpringForMe digital solutionN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
2 programs
Progression of Hematopoietic Diseases in Shanghai, ChinaN/A1 trial
Shanghai workersN/A1 trial
Active Trials
NCT00365014Completed10,757Est. Dec 2009
NCT00364520Completed2,000Est. Dec 2009
Kite Pharma
Kite PharmaCA - El Segundo
1 program
NewSpringForMe digital solutionN/A
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
NewSpringForMe digital solutionN/A
Novartis
NovartisBASEL, Switzerland
1 program
NewSpringForMe digital solutionN/A1 trial
Active Trials
NCT06148610Unknown170Est. Dec 2024
Sandoz
SandozAustria - Kundl
1 program
NewSpringForMe digital solutionN/A
Human BioSciences
Human BioSciencesWV - Martinsburg
1 program
Wearable activity sensorN/A1 trial
Active Trials
NCT04094844Completed372Est. Aug 2024
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
1 program
ex-vivo drug response assayN/A1 trial
Active Trials
NCT03488641Completed80Est. Aug 2021
MaaT Pharma
MaaT PharmaFrance - Lyon
1 program
MaaT033 capsulePHASE_11 trial
Active Trials
NCT04150393Completed21Est. Dec 2021
Rallybio
RallybioNEW HAVEN, CT
1 program
RLYB116 for InjectionPHASE_11 trial
Active Trials
NCT06797375Completed16Est. Feb 2026
Roche
RocheSTAVANGER NORWAY, Norway
1 program
Detection of microbial DNA in blood by SeptiFast TestPHASE_4

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GenentechDetection of microbial DNA in blood by SeptiFast Test
MSDOndansetron
RallybioRLYB116 for Injection
PulmotectPUL-042
MaaT PharmaMaaT033 capsule
NovartisNewSpringForMe digital solution
Human BioSciencesWearable activity sensor
Heidelberg Pharmaex-vivo drug response assay
Colorado TherapeuticsProgression of Hematopoietic Diseases in Shanghai, China
Colorado TherapeuticsShanghai workers

Clinical Trials (10)

Total enrollment: 13,666 patients across 10 trials

NCT01114165GenentechDetection of microbial DNA in blood by SeptiFast Test

Value of the LightCycler® SeptiFast Test MGRADE for the Pathogen Detection in Neutropenic Hematological Patients

Start: May 2010Est. completion: Sep 2012150 patients
Phase 4Completed
NCT00954941MSDOndansetron

Ondansetron Versus Aprepitant Plus Ondansetron for Emesis

Start: Nov 2009Est. completion: May 2015100 patients
Phase 2Completed
NCT06797375RallybioRLYB116 for Injection

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy Participants

Start: Apr 2025Est. completion: Feb 202616 patients
Phase 1Completed

A Multiple Ascending Dose Study of PUL-042 in Stem Cell Transplant Recipients

Start: Dec 2024Est. completion: May 20260
Phase 1Withdrawn
NCT04150393MaaT PharmaMaaT033 capsule

Safety and Tolerability Evaluation of MaaT033

Start: Oct 2020Est. completion: Dec 202121 patients
Phase 1Completed
NCT06148610NovartisNewSpringForMe digital solution

Evaluation of the Impact of the Use of NewSpringForMe on Transplanted Patients' Quality of Life and Support

Start: Sep 2022Est. completion: Dec 2024170 patients
N/AUnknown
NCT04094844Human BioSciencesWearable activity sensor

Health Information Technology System ("Roadmap 2.0") in the Context of Hematopoietic Cell Transplantation

Start: Sep 2020Est. completion: Aug 2024372 patients
N/ACompleted
NCT03488641Heidelberg Pharmaex-vivo drug response assay

Systematic and Mechanism-based Approach to Rational Treatment Trials of Blood Cancer

Start: Apr 2018Est. completion: Aug 202180 patients
N/ACompleted
NCT00365014Colorado TherapeuticsProgression of Hematopoietic Diseases in Shanghai, China

Progression of Hematopoietic Diseases in Shanghai, China

Start: Aug 2003Est. completion: Dec 200910,757 patients
N/ACompleted

Molecular Epidemiology of Benzene-exposed Workers.

Start: Aug 2003Est. completion: Dec 20092,000 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

17 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.